Baxter to invest in three Claris manufacturing plants

Baxter intends to invest in three Claris manufacturing plants with new aseptic manufacturing, lyophilization, and cytotoxics technology platforms.

“Baxter intends to flesh out those sites with new aseptic manufacturing, lyophilization, as well as cytotoxics, aseptic development and complex formulation technology platforms.”biopharmadive.com

• 1 source
• biopharmadive.comClosing Claris deal, Baxter set to invest in three new plants | BioPharma DiveJacob BellAug 3, 2017

Summarized from public sources; check the original articles before acting on it.